RxDoctor Payments Data

Debra Williams, DO

Psychiatry · Huntsville, ALNPI 1992762231

Payments from drug & device makers

$1,156in general payments, 2019–2025

Across 73 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$259
  • AbbVie$181
  • Lundbeck LLC$142
  • Sobi, Inc$100
  • Vanda Pharmaceuticals Inc.$71
  • Orexo US, Inc.$52
  • plus $351 from 12 others

What the payments were for

  • Food & beverage$1,15099%
  • Education$71%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,156 in reported general payments places this provider in the 60th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama

Medicare billing

Part B allowed, 2024
$14,956
Medicare patients
15
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl38$64,269
RexultiBrexpiprazole13$18,769
AuvelityDextromethorphan Hbr/Bupropion14$15,518
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl83$12,334
Lurasidone Hcl39$8,021
VyvanseLisdexamfetamine Dimesylate19$7,130
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine62$1,970
Desvenlafaxine Succinate ErDesvenlafaxine Succinate29$1,666
LoxapineLoxapine Succinate12$1,467
Divalproex Sodium ErDivalproex Sodium12$1,095
Zolpidem Tartrate ErZolpidem Tartrate11$1,083
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine21$678
Bupropion XlBupropion Hcl47$581
Desmopressin Acetate12$456
Sertraline Hcl71$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$16$64,26938 claims
Otsuka America Pharmaceutical, Inc.Rexulti$39$18,76913 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$33$7,13019 claims
Teva Pharmaceuticals USA, Inc.Loxapine$32$1,46712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 400 psychiatry providers in Alabama.

Other psychiatry in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →